ALK phase 3 trial confirms ACARIZAX efficacy in China

October 19, 2026 9:29 AM

ALK-Abelló A/S (Nasdaq Copenhagen: ALK B) announced positive topline results from a phase 3 bridging trial evaluating its house dust ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found